UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Protein analysis of extracellular vesicles to monitor and predict therapeutic response in metastatic breast cancer

Nature communications, 2021-05, Vol.12 (1), p.2536-2536, Article 2536

2021

Volltextzugriff (PDF)

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification

Cancer biology & medicine, 2022-06, Vol.19 (6), p.1-5

2022

Volltextzugriff (PDF)

Hot issues in triple-negative breast cancer

Cancer biology & medicine, 2024-02, Vol.20 (12), p.981-984

2024

Volltextzugriff (PDF)

Recent advances in the treatment of hormone receptor-positive/human epidermal growth factor 2-positive advanced breast cancer

Therapeutic Advances in Medical Oncology, 2021, Vol.13, p.17588359211013326-17588359211013326

2021

Volltextzugriff (PDF)

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer

International journal of cancer, 2014-10, Vol.135 (8), p.1961-1969

2014

Volltextzugriff (PDF)

Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial

Journal for immunotherapy of cancer, 2020-05, Vol.8 (1), p.e000696

2020

Volltextzugriff (PDF)

CSCO breast cancer guideline: precise, economical and oriental

Science China. Life sciences, 2020-09, Vol.63 (9), p.1410-1412

2020

Volltextzugriff (PDF)

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

Journal of clinical oncology, 2010-03, Vol.28 (8), p.1301-1307

2010

Volltextzugriff (PDF)

A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer

Nature communications, 2022-07, Vol.13 (1), p.4025-4025, Article 4025

2022

Volltextzugriff (PDF)

LSECtin on tumor-associated macrophages enhances breast cancer stemness via interaction with its receptor BTN3A3

Cell research, 2019-05, Vol.29 (5), p.365-378

2019

Volltextzugriff (PDF)

Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer

Chinese medical journal, 2023-06, Vol.136 (12), p.1459-1467

2023

Volltextzugriff (PDF)

tRNA-Derived Fragments as Novel Predictive Biomarkers for Trastuzumab-Resistant Breast Cancer

Cellular physiology and biochemistry, 2018-01, Vol.49 (2), p.419-431

2018

Volltextzugriff (PDF)

Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial

BMC medicine, 2022-12, Vol.20 (1), p.498-10, Article 498

2022

Volltextzugriff (PDF)

Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer

Breast (Edinburgh), 2022-12, Vol.66, p.255-261

2022

Volltextzugriff (PDF)

Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer

Journal of clinical oncology, 2013-06, Vol.31 (16), p.1947-1953

2013

Volltextzugriff (PDF)

Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial

Nature communications, 2024-03, Vol.15 (1), p.2153-2153, Article 2153

2024

Volltextzugriff (PDF)

Stellate ganglion, inflammation, and arrhythmias: a new perspective on neuroimmune regulation

Frontiers in cardiovascular medicine, 2024-09, Vol.11, p.1453127

2024

Volltextzugriff (PDF)

De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China

World journal of surgical oncology, 2024-08, Vol.22 (1), p.214-10

2024

Volltextzugriff (PDF)

Antibody drug conjugates in breast cancer in China: Highlights, challenges, and prospects

Cancer, 2024-04, Vol.130 (S8), p.1371-1377

2024

Volltextzugriff (PDF)

Electroacupuncture for post-stroke urinary incontinence: a systematic review and meta-analysis with trial sequential analysis

Frontiers in neurology, 2023-11, Vol.14, p.1282580-1282580

2023

Volltextzugriff (PDF)

Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis

Cancer chemotherapy and pharmacology, 2019-08, Vol.84 (2), p.373-382

2019

Volltextzugriff (PDF)

Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain

Frontiers in neurology, 2022-10, Vol.13, p.1002173-1002173

2022

Volltextzugriff (PDF)

Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients

BMC cancer, 2016-07, Vol.16 (1), p.526-526, Article 526

2016

Volltextzugriff (PDF)

1 – 25 von 286

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(199)
Mit Volltextzugriff
(227)

Publikationsform

Sprache

Englisch
(264)
Chinesisch
(22)

Erscheinungsjahr

n.n

Thema

Science & Technology
(175)
Life Sciences & Biomedicine
(154)
Oncology
(116)
Humans
(92)
Female
(78)
Breast Cancer
(64)
Middle Aged
(44)
Adult
(42)
Breast Neoplasms - Drug Therapy
(37)
Aged
(34)
Breast Neoplasms - Pathology
(28)
Metastasis
(24)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(23)
Treatment Outcome
(23)
Chemotherapy
(22)
Original
(22)
Tumors
(22)
Breast Neoplasms
(18)
China
(18)
Cancer Therapies
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Protein analysis of extracellular vesicles to monitor and predict therapeutic response in metastatic breast cancer

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification

Hot issues in triple-negative breast cancer

Recent advances in the treatment of hormone receptor-positive/human epidermal growth factor 2-positive advanced breast cancer

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial

CSCO breast cancer guideline: precise, economical and oriental

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer

LSECtin on tumor-associated macrophages enhances breast cancer stemness via interaction with its receptor BTN3A3

Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer

tRNA-Derived Fragments as Novel Predictive Biomarkers for Trastuzumab-Resistant Breast Cancer

Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial

Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer

Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer

Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial

Stellate ganglion, inflammation, and arrhythmias: a new perspective on neuroimmune regulation

De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China

Antibody drug conjugates in breast cancer in China: Highlights, challenges, and prospects

Electroacupuncture for post-stroke urinary incontinence: a systematic review and meta-analysis with trial sequential analysis

Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis

Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain

Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients

Suchergebnisse filtern